Genmab A/S at JPMorgan Healthcare Conference Transcript
Good afternoon, everyone. I'm James Quigley, European pharma and biotech analyst at JPMorgan. It's my pleasure to welcome you all to the Genmab presentation.
With us today is Genmab's CEO, Jan van de Winkel. After Jan's presentation, there'll be a breakout session in the Yorkshire Room, which is out the door to the back and left.
So with that, over to you, Jan.
/-- -
Thank you very much. So good afternoon, everybody. It's a real pleasure to join you once again at the Annual JPMorgan Healthcare Conference as we kick off 2020. So welcome to those of you who are participating via webcast as well. The slides from today's presentation will be made available for download in PDF format at the end of the presentation after the event.
So let's now get started. And this is what you're very familiar with. This presentation may contain forward
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |